TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31436190

Group type: COMPARATOR
Intervention: PPV with no ILM peeling
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: PPV with macular peeling
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: PPV with macular plus peripapillary peeling
Number of subjects: 287
Study: 27797683

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 500 mg daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26029855

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (3 g per day, 1 g before each meal) with a low-calorie diet
Number of subjects: 90
Study: 21959840

Group type: EXPERIMENTAL
Intervention: Minimally invasive (MIS) multilevel hemilaminectomy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Open multilevel hemilaminectomy
Number of subjects: 54
Study: 21442805

Group type: EXPERIMENTAL
Intervention: Electroacupuncture intervention in the observation group (48 cases)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional treatment in the control group (20 cases)
Number of subjects: 68
Study: 19364625

Group type: EXPERIMENTAL
Intervention: Participant-led appointments
Number of subjects: 23

Group type: COMPARATOR
Intervention: Recruiter-led appointments
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Communication techniques (open questions, pauses, ceding the floor)
Number of subjects: 23
Study: 16802291

Group type: EXPERIMENTAL
Intervention: Celecoxib (800 mg/day)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 15578632

Group type: EXPERIMENTAL
Intervention: Ticlopidine test formulation from Apotex do Brasil, 250 mg dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticlid from Sanofi‐Synthelabo, 250 mg dose
Number of subjects: 0
Study: 11386398

Group type: EXPERIMENTAL
Intervention: Quadriceps training
Number of subjects: 80
Study: 9390588

Group type: EXPERIMENTAL
Intervention: Nicardipine 0.5 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nicardipine 1 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nicardipine 2 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nicardipine 4 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 106
Study: 7910722

Group type: EXPERIMENTAL
Intervention: GLQ223 administered intravenously at doses of 36 and 50 micrograms/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GLQ223 administered intravenously at doses of 8, 16, 24, 36, and 50 micrograms/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GLQ223 administered intravenously
Number of subjects: 22
Study: 3332564

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31711134

Group type: EXPERIMENTAL
Intervention: Predictive HTE analysis using risk-modeling approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive HTE analysis using effect-modeling approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk-modeling approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effect-modeling approaches
Number of subjects: 0
Study: 31578080

Group type: EXPERIMENTAL
Intervention: Lp(a) lowering by 50 mg/dL (105 nmol/L) for 5 years
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Lp(a) lowering by 99 mg/dL (212 nmol/L) for 5 years
Number of subjects: 2527

Group type: COMPARATOR
Intervention: Individuals with Lp(a)<10 mg/dL (18 nmol/L)
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Individuals with Lp(a) 10 to 49 mg/dL (18-104 nmol/L)
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Individuals with Lp(a) 50 to 99 mg/dL (105-213 nmol/L)
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Individuals with Lp(a) ≥100 mg/dL (≥214 nmol/L)
Number of subjects: 2527
Study: 26554107

Group type: EXPERIMENTAL
Intervention: Vicryl rapide
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Catgut
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dexon
Number of subjects: 96

Group type: COMPARATOR
Intervention: All three groups (Vicryl rapide, Catgut, Dexon)
Number of subjects: 96
Study: 24077867

Group type: EXPERIMENTAL
Intervention: Locking plate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-locking plate
Number of subjects: 52
Study: 21712481

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (10 mg oral) administered 2 days per week before physiotherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo administered 2 days per week before physiotherapy
Number of subjects: 16
Study: 19012955

Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 12306
Study: 16919578

Group type: EXPERIMENTAL
Intervention: Myocardial oxidative metabolism (kmono) in NIDCM patients
Number of subjects: 7

Group type: COMPARATOR
Intervention: Myocardial oxidative metabolism (kmono) in normal subjects
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rate-pressure product (RPP) in NIDCM patients
Number of subjects: 7

Group type: COMPARATOR
Intervention: Rate-pressure product (RPP) in normal subjects
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: kmono/RPP ratio in NIDCM patients
Number of subjects: 7

Group type: COMPARATOR
Intervention: kmono/RPP ratio in normal subjects
Number of subjects: 7
Study: 14586387

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbon monoxide (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air breathing (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Number of subjects: 12
Study: 10740559

Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg pretreatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline pretreatment (Control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg pretreatment
Number of subjects: 90
Study: 9176539

Group type: EXPERIMENTAL
Intervention: Salmeterol 100, 200, and 400 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Salbutamol 600, 1200, and 2400 micrograms
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8471369

Group type: EXPERIMENTAL
Intervention: Transarterial technique with 1% mepivacaine 45 ml with adrenaline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Perivascular technique with 1% mepivacaine 45 ml with adrenaline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Computed tomography after contrast medium added to 0.5% bupivacaine 40 ml
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both techniques (perivascular and transarterial)
Number of subjects: 50
Study: 3535687

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride
Number of subjects: 81

Group type: COMPARATOR
Intervention: Erythromycin stearate
Number of subjects: 81
Study: 31806099

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment for 3 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d for 3 months (after initial no treatment)
Number of subjects: 48
Study: 29773846

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for appetite
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Days spent in acute hospital post-ICU
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Serum C-reactive protein (CRP) concentration
Number of subjects: 193
Study: 26581199

Group type: EXPERIMENTAL
Intervention: recMAGE-A3 combined with AS15 immunostimulant administered intramuscularly (group A, n=13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: recMAGE-A3 combined with AS15 immunostimulant administered intradermally/subcutaneously (group B, n=12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both routes of immunization (i.m. and i.d./s.c.)
Number of subjects: 25
Study: 24814583

Group type: EXPERIMENTAL
Intervention: Perioperative selective decontamination of the digestive tract (SDD) with colistin, tobramycin, and amphotericin B in addition to standard antibiotic prophylaxis
Number of subjects: 762

Group type: COMPARATOR
Intervention: Standard antibiotic prophylaxis alone
Number of subjects: 762
Study: 22284330

Group type: EXPERIMENTAL
Intervention: Proximal balloon occlusion
Number of subjects: 62

Group type: COMPARATOR
Intervention: Filter protection
Number of subjects: 62
Study: 19608584

Group type: EXPERIMENTAL
Intervention: Sputum strategy (SS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clinical strategy (CS)
Number of subjects: 20
Study: 18280560

Group type: EXPERIMENTAL
Intervention: Telephone dietary counseling
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standardized, written nutritional information
Number of subjects: 74
Study: 15877297

Group type: EXPERIMENTAL
Intervention: Cortitrol supplementation
Number of subjects: 0
Study: 12665398

Group type: EXPERIMENTAL
Intervention: Clozapine (mean 274.2 mg/day)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Olanzapine (mean 16.6 mg/day)
Number of subjects: 490
Study: 10232630

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) group
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis-related diabetes mellitus (CFDM) group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 8826973

Group type: EXPERIMENTAL
Intervention: 2-h insulin levels in individuals who developed NIDDM
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Mean 2-h insulin concentration changes
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Fasting insulin levels
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Baseline fasting and 2-h glucose concentrations
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Fasting and 2-h insulin concentrations
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Fasting and 2-h glucose levels
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Insulin levels
Number of subjects: 838
Study: 8391072

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3105368

Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin ointment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Bland ointment
Number of subjects: 34
Study: 29191442

Group type: EXPERIMENTAL
Intervention: Circumpatellar electrocautery plus patellar resurfacing
Number of subjects: 53

Group type: COMPARATOR
Intervention: Circumpatellar electrocautery only
Number of subjects: 53
Study: 27131044

Group type: EXPERIMENTAL
Intervention: Cine-derived dyscontractility index (CDI)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cine-derived indices
Number of subjects: 52

Group type: COMPARATOR
Intervention: tMRI-based indices
Number of subjects: 52
Study: 25668345

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High sodium intake
Number of subjects: 24
Study: 22725990

Group type: EXPERIMENTAL
Intervention: Transcrestal balloon technique (B)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional osteotome approach (C)
Number of subjects: 10
Study: 20151940

Group type: EXPERIMENTAL
Intervention: Zinc and vitamin A supplementation (10 mg elemental zinc per day and one-half of a 25,000 IU vitamin A tablet every other day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zinc and vitamin A supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 48
Study: 19177660

Group type: EXPERIMENTAL
Intervention: Physical therapy exercises 'Brain gymnastics' (n = 41)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard rehabilitative treatment (n = 41)
Number of subjects: 83
Study: 16886964

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12648639

Group type: EXPERIMENTAL
Intervention: Group 1a (primary posterior capsulotomy and anterior vitrectomy)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group 1b (optic capture in addition)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group 2a (primary posterior capsulotomy without anterior vitrectomy)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group 2b (optic capture in addition)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group 2c (in-the-bag IOL implantation without opening the posterior capsule)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Eyes that developed PCO
Number of subjects: 34
Study: 10401799

Group type: EXPERIMENTAL
Intervention: Soy-based formula with sucrose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Soy-based formula with lactose
Number of subjects: 200
Study: 7854859

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin
Number of subjects: 10
Study: 2811556

Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous dexamethasone before the procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1108720

Group type: EXPERIMENTAL
Intervention: 5 mg of terbutaline
Number of subjects: 5

Group type: COMPARATOR
Intervention: 20 mg of metaproterenol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31712211

Group type: EXPERIMENTAL
Intervention: CVC lock solution with taurolidine‐citrate‐heparin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Heparin alone (placebo)
Number of subjects: 150
Study: 30778572

Group type: EXPERIMENTAL
Intervention: L-OTM (equivalent to L-ITM)
Number of subjects: 600

Group type: COMPARATOR
Intervention: COM (commercial levels of inorganic minerals)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: COM and OTM
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: L-OTM
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: COM, L-OTM, and OTM
Number of subjects: 600
Study: 28642810

Group type: EXPERIMENTAL
Intervention: low-amount/moderate-intensity (10KKW/50%) exercise
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: high-amount/moderate-intensity (16KKW/50%) exercise
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: high-amount/vigorous-intensity (16KKW/75%) exercise
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Clinical Lifestyle (combined diet plus low-amount/moderate-intensity exercise) intervention
Number of subjects: 169

Group type: COMPARATOR
Intervention: All four interventions combined
Number of subjects: 169
Study: 25820066

Group type: EXPERIMENTAL
Intervention: AVA vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24517059

Group type: EXPERIMENTAL
Intervention: High dose Jinhua Qinggan Granule (10 g each time, 3 times daily for 5 days)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Low dose Jinhua Qinggan Granule (5 g JHG + 5 g placebo each time, 3 times daily for 5 days)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo control (10 g placebo each time, 3 times daily for 5 days)
Number of subjects: 136
Study: 21499183

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitor with intravenous insulin infusion and rescue glucose (tight glycemic control arm)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Real-time continuous glucose monitor (standard care arm)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Real-time continuous glucose monitor alarms set at 60 mg/dL (3.3 mmol/L)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Real-time continuous glucose monitor alarms increased to 70 mg/dL (3.9 mmol/L)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Overall false hypoglycemia alarms
Number of subjects: 311
Study: 19228385

Group type: EXPERIMENTAL
Intervention: Albendazole treatment every four months for 12 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo treatment every four months for 12 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Albendazole treatment at baseline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo treatment at baseline
Number of subjects: 50
Study: 17008814

Group type: EXPERIMENTAL
Intervention: Low-frequency, noncontact ultrasound therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard of care (historical control)
Number of subjects: 23
Study: 15194369

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prograf
Number of subjects: 33
Study: 11071580

Group type: EXPERIMENTAL
Intervention: Pharmaceutical-grade collagen hydrolysate (PCH) 10 g daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcitonin plus PCH
Number of subjects: 0
Study: 9267682

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg under fed conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg under fasting conditions
Number of subjects: 12
Study: 7892773

Group type: EXPERIMENTAL
Intervention: 35% carbon dioxide challenge in situational or natural phenomena phobics
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 35% carbon dioxide challenge in animal phobics
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 58
Study: 3299441

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine and mental arithmetic
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo and mental arithmetic
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine alone
Number of subjects: 18
Study: 31599141

Group type: EXPERIMENTAL
Intervention: Cor-Knot titanium fastener
Number of subjects: 221

Group type: COMPARATOR
Intervention: Hand-tied knots
Number of subjects: 221
Study: 29086586

Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Number of subjects: 54
Study: 28561421

Group type: EXPERIMENTAL
Intervention: Etofenamate patch
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diclofenac patch
Number of subjects: 24
Study: 25724656

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (2 μg/kg, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 20
Study: 24051968

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus paracasei subsp. paracasei F-19
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard medical treatment (Control)
Number of subjects: 32
Study: 21360062

Group type: EXPERIMENTAL
Intervention: Value-added education
Number of subjects: 2621
Study: 18335109

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 534

Group type: COMPARATOR
Intervention: Resin composite (white fillings)
Number of subjects: 534
Study: 16573795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 14594787

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg elemental calcium daily for 12 months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 10980230

Group type: EXPERIMENTAL
Intervention: New index using 2-dimensional measurement of the reconstructed aortic arch
Number of subjects: 0
Study: 8781012

Group type: EXPERIMENTAL
Intervention: Relaxation techniques training at home
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Routine blood pressure measurement by a health professional
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Reading self-learning packages
Number of subjects: 590

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 590
Study: 1395211

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE-I) added to conventional therapy including digitalis, diuretics, or vasodilators
Number of subjects: 0
Study: 6347233

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg orally daily for 2 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30702960

Group type: EXPERIMENTAL
Intervention: Graphic Organizers (GO)
Number of subjects: 31
Study: 29927746

Group type: EXPERIMENTAL
Intervention: Acupressure and standard antenatal care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 30
Study: 26900078

Group type: EXPERIMENTAL
Intervention: 5 mg aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24859440

Group type: EXPERIMENTAL
Intervention: Ultralow dose computerized tomography (sub mSv range)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ultralow dose computerized tomography (filtered back projection)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ultralow dose computerized tomography (adaptive statistical iterative reconstruction)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ultralow dose computerized tomography (model based iterative reconstruction)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ultralow dose computerized tomography
Number of subjects: 48
Study: 21536208

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (Kuraray Medical, Okayama, Japan)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Transbond XT (3M Unitek, Monrovia, Calif)
Number of subjects: 14
Study: 19427576

Group type: EXPERIMENTAL
Intervention: Telephone follow-up (Group B)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Mailed follow-up (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 98
Study: 17001135

Group type: EXPERIMENTAL
Intervention: discharge summary curriculum
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: curriculum plus individualized feedback
Number of subjects: 59

Group type: COMPARATOR
Intervention: control group
Number of subjects: 59
Study: 15188499

Group type: EXPERIMENTAL
Intervention: H pylori-positive NUD patients receiving 10-day triple eradication therapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: NUD patients (overall)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: NUD patients before and after H pylori eradication
Number of subjects: 33

Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 33
Study: 11122299

Group type: EXPERIMENTAL
Intervention: 5% saline
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3% saline
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 38
Study: 9491847

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy regimen
Number of subjects: 40